SUPAC, which stands for Scale-Up & Post-Approval Changes, refers to a series of FDA guidance documents that outline regulatory expectations for changes made to a drug product after it has been approved. These changes may include modifications at the manufacturing site, equipment upgrades, process scale-up, & adjustments to formulation or packaging.
FDA & American Association of Pharmacueticals scientists (AAPS) provided the scientific foundation for the scale-up & post approval changes.
Provides guidelines for post approval changes for:
- Components & Compositions
- Process & equipment
- Site of manufacturing
- In vitro dissolution and in vivo bioequivalence
- Scale-up of batch size
Advantages:
- Allows manufacturers to optimize processes, adopt better technology, & improve efficiency after approval.
- Properly classified SUPAC changes can speed up approval of modifications.
- Members of the production & quality control divisions can readily observe scale-up runs.
- Access to engineering department personnel is provided for equipment installation, maintenance, & repair.
Disadvantages:
- Any problem in manufacturing will be directed towards its own pilot-plant personnel.
- Conducting additional studies (stability, bioequivalence, validation) increases operational expenses.
- The frequency of direct interaction of the formulator with the production personnel in the manufacturing area will be reduced.
- Understanding & applying SUPAC guidelines requires strong regulatory expertise.
MBH/AB